Micafungin

證據等級: L5

預測適應症: 1 個

Micafungin: From Invasive Candidiasis to Urinary Tract Infection

One-Sentence Summary

Micafungin is an echinocandin class antifungal agent approved in multiple countries for the treatment and prophylaxis of invasive candidiasis and esophageal candidiasis. The TxGNN model predicts it may be effective for Urinary Tract Infection (Candida UTI), with 0 clinical trials and 13 publications currently supporting this direction — though the mechanistic basis for this indication remains pharmacokinetically controversial.

Quick Overview

Item	Content
Original Indication	Invasive candidiasis; esophageal candidiasis; prophylaxis in hematopoietic stem cell transplant recipients
Predicted New Indication	Urinary Tract Infection (Candida UTI)
TxGNN Prediction Score	99.03%
Evidence Level	L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Micafungin belongs to the echinocandin class of antifungal agents. Its mechanism of action is the inhibition of β-1,3-D-glucan synthase — an enzyme essential for fungal cell wall biosynthesis that has no mammalian equivalent. This mechanism is broadly fungicidal against Candida species, including many azole-resistant strains such as Candida krusei and Candida glabrata. Because urinary tract infections caused by Candida (candiduria) share the same pathogens treated by micafungin in systemic settings, the TxGNN model likely identified this mechanistic overlap and awarded a high prediction score.

However, there is a well-recognised pharmacokinetic barrier for this indication: echinocandins including micafungin are excreted in urine at extremely low concentrations — less than 1% of the administered dose reaches the urine as active drug. IDSA guidelines therefore do not recommend echinocandins as first-line agents for Candida UTI, precisely because urine drug concentrations are unlikely to achieve the minimum inhibitory concentration (MIC) at standard doses. The high TxGNN score (0.990) most plausibly reflects the drug’s general anti-Candida activity rather than site-specific pharmacodynamic evidence for the urinary compartment.

Despite this limitation, the published literature documents a niche where micafungin has been used off-label with reported success: patients with fluconazole-resistant or azole-intolerant Candida UTI (e.g., transplant recipients, premature neonates, patients with hepatic dysfunction), particularly when alternative options are exhausted. One pharmacokinetic study (PMID 27424599) argued that therapeutic drug monitoring of urinary micafungin levels could optimise dosing for selected cases. This positions micafungin as a potential salvage-therapy option rather than a broad repurposing candidate, and the current evidence base does not yet support a formal development programme for this indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27587066	2016	Retrospective Cohort	Int J Urol Nephrol	Examined candiduria elimination rates in micafungin-treated hospitalised patients; echinocandins active against azole-resistant Candida but limited by low urinary concentrations
29109159	2018	Multi-site Retrospective	Antimicrob Agents Chemother	Characterised candiduria management in 305 hospitalised patients across multiple institutions; found significant antifungal overuse in asymptomatic candiduria contrary to guidelines
35146837	2022	Retrospective Case Series	Pediatrics International	Reported treatment outcomes of critically ill PICU patients receiving micafungin for hospital-acquired Candida UTIs; analysed success rates across Candida species
27424599	2016	Pharmacokinetic Study	Int J Antimicrob Agents	Six cases of Candida UTI (including 4 fluconazole-resistant) successfully treated with micafungin; proposed that therapeutic drug monitoring of urinary levels may enable optimal pharmacodynamic targeting
26937340	2016	Case Series	Med Mycol Case Rep	Five cases of candiduria treated with parenteral micafungin for ≥6 days; all achieved resolution of fungal growth within 30 days of treatment completion
31111613	2019	Case Report	Transplant Infect Dis	Successful eradication of chronic symptomatic Candida krusei UTI with increased-dose micafungin in a liver–kidney transplant recipient with intrinsic fluconazole resistance
40765059	2025	Case Report	J Pharm Health Care Sci	Pyelonephritis and bacteraemia from fluconazole-resistant Candida glabrata in a patient on SGLT2 inhibitor; successfully treated with micafungin
38827222	2024	Case Report	Front Pediatrics	Candida glabrata UTI in a premature neonate (NICU) treated successfully with micafungin; highlighted rising incidence of non-albicans Candida in vulnerable neonatal populations
38681664	2024	Case Report	Med Mycol Case Rep	Unilateral renal fungus ball (micafungin-sensitive Candida glabrata) managed with combined antifungal therapy and endoscopic extraction
33520520	2020	Case Report	Cureus	Candida auris UTI in a nursing home patient with multiple comorbidities; discussed micafungin as one of the few active options against this multidrug-resistant emerging pathogen

India Market Information

Micafungin is currently not marketed in India. No product registrations are on record (0 authorisations).

Safety Considerations

Drug Interactions (all Moderate level, source: DDInter):

Interacting Drug	Level	Clinical Note
Amphotericin B	Moderate	Potential additive nephrotoxicity; monitor renal function closely
Nitisinone	Moderate	Possible pharmacokinetic interaction; monitor for adverse effects
Everolimus	Moderate	Micafungin may increase everolimus plasma exposure; dose adjustment and level monitoring may be required
Ribociclib	Moderate	Monitor for increased drug exposure and QTc effects
Sirolimus	Moderate	Micafungin has been reported to increase sirolimus AUC; monitor trough levels and toxicity

Please refer to the package insert for complete warnings and contraindications, as this data was not available for review.

Conclusion and Next Steps

Decision: Hold

Rationale: Although TxGNN assigns a high prediction score (99.03%) reflecting micafungin’s potent anti-Candida activity, the fundamental pharmacokinetic barrier — less than 1% urinary excretion of active drug — directly undermines the mechanistic premise for treating urinary tract infections. The entire current evidence base (L4) consists of case reports, small case series, and retrospective studies with no registered prospective clinical trials, placing this firmly in the research-question stage. IDSA guidelines explicitly advise against echinocandins for Candida UTI except in highly selected refractory scenarios.

To proceed, the following is needed:

PK/PD validation: Prospective pharmacokinetic data confirming that urinary micafungin concentrations at clinically safe doses can reliably exceed the MIC for target Candida species
Defined patient population: Identify a specific subgroup (e.g., fluconazole-resistant Candida UTI in transplant recipients) where the benefit–risk calculation favours off-label use
Prospective study: At least one Phase 2 or prospective observational study before clinical development can be justified
Regulatory package insert review: Obtain CDSCO/TFDA package insert to document approved warnings and contraindications (currently a blocking data gap)
MOA data: Retrieve full DrugBank MOA entry to complete mechanistic analysis
India regulatory pathway: Assess whether compassionate use or off-label prescribing frameworks in India would apply for refractory candiduria cases while formal evidence is gathered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.